1
|
Mein S, Wuyckens S, Li X, Both S, Carabe A, Vera MC, Engwall E, Francesco F, Graeff C, Gu W, Hong L, Inaniwa T, Janssens G, de Jong B, Li T, Liang X, Liu G, Lomax A, Mackie T, Mairani A, Mazal A, Nesteruk KP, Paganetti H, Moreno JMP, Schreuder N, Soukup M, Tanaka S, Tessonnier T, Volz L, Zhao L, Ding X. Particle arc therapy: Status and potential. Radiother Oncol 2024:110434. [PMID: 39009306 DOI: 10.1016/j.radonc.2024.110434] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/09/2023] [Revised: 06/23/2024] [Accepted: 07/10/2024] [Indexed: 07/17/2024]
Abstract
There is a rising interest in developing and utilizing arc delivery techniques with charged particle beams, e.g., proton, carbon or other ions, for clinical implementation. In this work, perspectives from the European Society for Radiotherapy and Oncology (ESTRO) 2022 physics workshop on particle arc therapy are reported. This outlook provides an outline and prospective vision for the path forward to clinically deliverable proton, carbon, and other ion arc treatments. Through the collaboration among industry, academic, and clinical research and development, the scientific landscape and outlook for particle arc therapy are presented here to help our community understand the physics, radiobiology, and clinical principles. The work is presented in three main sections: (i) treatment planning, (ii) treatment delivery, and (iii) clinical outlook.
Collapse
Affiliation(s)
- Stewart Mein
- Department of Radiation Oncology, University of Pennsylvania, Philadelphia, PA, USA; Heidelberg Ion-Beam Therapy Center (HIT), Heidelberg, Germany; Division of Molecular and Translational Radiation Oncology, National Center for Tumor Diseases (NCT), Heidelberg University Hospital, Heidelberg, Germany; Heidelberg Institute of Radiation Oncology (HIRO), German Cancer Research Center (DKFZ), Heidelberg, Germany and German Cancer Consortium (DKTK), Heidelberg, Germany; Clinical Cooperation Unit Radiation Oncology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
| | - Sophie Wuyckens
- UCLouvain, Molecular Imaging, Radiotherapy and Oncology (MIRO), Brussels, Belgium
| | - Xiaoqiang Li
- Department of Radiation Oncology, Corewell Health, William Beaumont University Hospital, Proton Therapy Center, Royal Oak, MI, USA
| | - Stefan Both
- Department of Radiation Oncology, University Medical Center Groningen, Groningen, The Netherlands
| | | | - Macarena Chocan Vera
- UCLouvain, Molecular Imaging, Radiotherapy and Oncology (MIRO), Brussels, Belgium
| | | | | | - Christian Graeff
- GSI Helmholtzzentrum für Schwerionenforschung, Darmstadt, Germany; Technische Universität Darmstadt, Institut für Physik Kondensierter Materie, Darmstadt, Germany
| | - Wenbo Gu
- Department of Radiation Oncology, University of Pennsylvania, Philadelphia, PA, USA
| | - Liu Hong
- Ion Beam Applications SA, Louvain-la-Neuve, Belgium
| | - Taku Inaniwa
- Department of Accelerator and Medical Physics, Institute for Quantum Medical Science, National Institutes for Quantum Science and Technology, Chiba, Japan; Department of Medical Physics and Engineering, Graduate School of Medicine, Division of Health Sciences, Osaka University, Osaka, Japan
| | | | - Bas de Jong
- Department of Radiation Oncology, University Medical Center Groningen, Groningen, The Netherlands
| | - Taoran Li
- Department of Radiation Oncology, University of Pennsylvania, Philadelphia, PA, USA
| | - Xiaoying Liang
- Department of Radiation Oncology, Mayo Clinic Jacksonville, Jacksonville, FL, USA
| | - Gang Liu
- Department of Radiation Oncology, Corewell Health, William Beaumont University Hospital, Proton Therapy Center, Royal Oak, MI, USA; Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
| | - Antony Lomax
- Centre for Proton Therapy, Paul Scherrer Institute, Villigen, Switzerland; ETH, Department of Physics, Zürich, Switzerland
| | - Thomas Mackie
- Department of Human Oncology, University of Wisconsin School of Medicine, Madison, WI, USA
| | - Andrea Mairani
- Heidelberg Ion-Beam Therapy Center (HIT), Heidelberg, Germany; National Centre of Oncological Hadrontherapy (CNAO), Medical Physics, Pavia, Italy
| | | | - Konrad P Nesteruk
- Department of Radiation Oncology, Massachusetts General Hospital, Boston, USA; Harvard Medical School, Boston, USA
| | - Harald Paganetti
- Department of Radiation Oncology, Massachusetts General Hospital, Boston, USA; Harvard Medical School, Boston, USA
| | | | | | | | - Sodai Tanaka
- Department of Accelerator and Medical Physics, Institute for Quantum Medical Science, National Institutes for Quantum Science and Technology, Chiba, Japan
| | | | - Lennart Volz
- GSI Helmholtzzentrum für Schwerionenforschung, Darmstadt, Germany; Technische Universität Darmstadt, Institut für Physik Kondensierter Materie, Darmstadt, Germany
| | - Lewei Zhao
- Department of Radiation Oncology, Stanford University, Stanford, CA, USA
| | - Xuanfeng Ding
- Department of Radiation Oncology, Corewell Health, William Beaumont University Hospital, Proton Therapy Center, Royal Oak, MI, USA.
| |
Collapse
|
2
|
Garrido-Hernandez G, Henjum H, Winter RM, Alsaker MD, Danielsen S, Boer CG, Ytre-Hauge KS, Redalen KR. Interim 18F-FDG-PET based response-adaptive dose escalation of proton therapy for head and neck cancer: a treatment planning feasibility study. Phys Med 2024; 123:103404. [PMID: 38852365 DOI: 10.1016/j.ejmp.2024.103404] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/28/2023] [Revised: 05/06/2024] [Accepted: 06/05/2024] [Indexed: 06/11/2024] Open
Abstract
BACKGROUND Image-driven dose escalation to tumor subvolumes has been proposed to improve treatment outcome in head and neck cancer (HNC). We used 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET) acquired at baseline and into treatment (interim) to identify biologic target volumes (BTVs). We assessed the feasibility of interim dose escalation to the BTV with proton therapy by simulating the effects to organs at risk (OARs). METHODS We used the semiautomated just-enough-interaction (JEI) method to identify BTVs in 18F-FDG-PET images from nine HNC patients. Between baseline and interim FDG-PET, patients received photon radiotherapy. BTV was identified assuming that high standardized uptake value (SUV) at interim reflected tumor radioresistance. Using Eclipse (Varian Medical Systems), we simulated a 10% (6.8 Gy(RBE1.1)) and 20% (13.6 Gy(RBE1.1)) dose escalation to the BTV with protons and compared results with proton plans without dose escalation. RESULTS At interim 18F-FDG-PET, radiotherapy resulted in reduced SUV compared to baseline. However, spatial overlap between high-SUV regions at baseline and interim allowed for BTV identification. Proton therapy planning demonstrated that dose escalation to the BTV was feasible, and except for some 20% dose escalation plans, OAR doses did not significantly increase. CONCLUSION Our in silico analysis demonstrated the potential for interim 18F-FDG-PET response-adaptive dose escalation to the BTV with proton therapy. This approach may give more efficient treatment to HNC with radioresistant tumor subvolumes without increasing normal tissue toxicity. Studies in larger cohorts are required to determine the full potential for interim 18F-FDG-PET-guided dose escalation of proton therapy in HNC.
Collapse
Affiliation(s)
| | - Helge Henjum
- Department of Physics and Technology, University of Bergen, Bergen, Norway
| | - René Mario Winter
- Department of Physics, Norwegian University of Science and Technology, Trondheim, Norway
| | - Mirjam Delange Alsaker
- Department of Radiotherapy, Cancer Clinic, St. Olav's Hospital, Trondheim University Hospital, Trondheim, Norway
| | - Signe Danielsen
- Department of Physics, Norwegian University of Science and Technology, Trondheim, Norway; Department of Oncology, St. Olav's Hospital, Trondheim University Hospital, Trondheim, Norway
| | | | | | - Kathrine Røe Redalen
- Department of Physics, Norwegian University of Science and Technology, Trondheim, Norway
| |
Collapse
|
3
|
A novel optimization algorithm for enabling dynamically collimated proton arc therapy. Sci Rep 2022; 12:21731. [PMID: 36526670 PMCID: PMC9758145 DOI: 10.1038/s41598-022-25774-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/12/2022] [Accepted: 12/05/2022] [Indexed: 12/23/2022] Open
Abstract
The advent of energy-specific collimation in pencil beam scanning (PBS) proton therapy has led to an improved lateral dose conformity for a variety of treatment sites, resulting in better healthy tissue sparing. Arc PBS delivery has also been proposed to enhance high-dose conformity about the intended target, reduce skin toxicity, and improve plan robustness. The goal of this work was to determine if the combination of proton arc and energy-specific collimation can generate better dose distributions as a logical next step to maximize the dosimetric advantages of proton therapy. Plans were optimized using a novel DyNamically collimated proton Arc (DNA) genetic optimization algorithm that was designed specifically for the application of proton arc therapy. A treatment planning comparison study was performed by generating an uncollimated two-field intensity modulated proton therapy and partial arc treatments and then replanning these treatments using energy-specific collimation as delivered by a dynamic collimation system, which is a novel collimation technology for PBS. As such, we refer to this novel treatment paradigm as Dynamically Collimated Proton Arc Therapy (DC-PAT). Arc deliveries achieved a superior target conformity and improved organ at risk (OAR) sparing relative to their two-field counterparts at the cost of an increase to the low-dose, high-volume region of the healthy brain. The incorporation of DC-PAT using the DNA optimizer was shown to further improve the tumor dose conformity. When compared to the uncollimated proton arc treatments, the mean dose to the 10mm of surrounding healthy tissue was reduced by 11.4% with the addition of collimation without meaningfully affecting the maximum skin dose (less than 1% change) relative to a multi-field treatment. In this case study, DC-PAT could better spare specific OARs while maintaining better target coverage compared to uncollimated proton arc treatments. While this work presents a proof-of-concept integration of two emerging technologies, the results are promising and suggest that the addition of these two techniques can lead to superior treatment plans warranting further development.
Collapse
|
4
|
Worm ES, Hansen R, Høyer M, Weber B, Mortensen H, Poulsen PR. Uniform versus non-uniform dose prescription for proton stereotactic body radiotherapy of liver tumors investigated by extensive motion-including treatment simulations. Phys Med Biol 2021; 66. [PMID: 34544071 DOI: 10.1088/1361-6560/ac2880] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/08/2021] [Accepted: 09/20/2021] [Indexed: 12/24/2022]
Abstract
Compared to x-ray-based stereotactic body radiotherapy (SBRT) of liver cancer, proton SBRT may reduce the normal liver tissue dose. For an optimal trade-off between target and liver dose, a non-uniform dose prescription is often applied in x-ray SBRT, but lacks investigation for proton SBRT. Also, proton SBRT is prone to breathing-induced motion-uncertainties causing target mishit or dose alterations by interplay with the proton delivery. This study investigated non-uniform and uniform dose prescription in proton-based liver SBRT, including effects of rigid target motion observed during planning-4DCT and treatment. The study was based on 42 x-ray SBRT fractions delivered to 14 patients under electromagnetic motion-monitoring. For each patient, a non-uniform and uniform proton plan were made. The uniform plan was renormalized to be iso-toxic with the non-uniform plan using a NTCP model for radiation-induced liver disease. The motion data were used in treatment simulations to estimate the delivered target dose with rigid motion. Treatment simulations were performed with and without a repainting scheme designed to mitigate interplay effects. Including rigid motion, the achieved CTV mean dose after three fractions delivered without repainting was on average (±SD) 24.8 ± 8.4% higher and the D98%was 16.2 ± 11.3% higher for non-uniform plans than for uniform plans. The interplay-induced increase in D2%relative to the static plans was reduced from 3.2 ± 4.1% without repainting to -0.5 ± 1.7% with repainting for non-uniform plans and from 1.5 ± 2.0% to 0.1 ± 1.3% for uniform plans. Considerable differences were observed between estimated CTV doses based on 4DCT motion and intra-treatment motion. In conclusion, non-uniform dose prescription in proton SBRT may provide considerably higher tumor doses than uniform prescription for the same complication risk. Due to motion variability, target doses estimated from 4DCT motion may not accurately reflect the delivered dose. Future studies including modelling of deformations and associated range uncertainties are warranted to confirm the findings.
Collapse
Affiliation(s)
| | - Rune Hansen
- Department of Oncology, Aarhus University Hospital, Aarhus, Denmark
| | - Morten Høyer
- Danish Center for Particle Therapy, Aarhus University Hospital, Aarhus, Denmark
| | - Britta Weber
- Department of Oncology, Aarhus University Hospital, Aarhus, Denmark.,Danish Center for Particle Therapy, Aarhus University Hospital, Aarhus, Denmark
| | - Hanna Mortensen
- Danish Center for Particle Therapy, Aarhus University Hospital, Aarhus, Denmark
| | - Per Rugaard Poulsen
- Department of Oncology, Aarhus University Hospital, Aarhus, Denmark.,Danish Center for Particle Therapy, Aarhus University Hospital, Aarhus, Denmark.,Department of Clinical Medicine, Aarhus University, Aarhus, Denmark
| |
Collapse
|
5
|
Mazal A, Vera Sanchez JA, Sanchez-Parcerisa D, Udias JM, España S, Sanchez-Tembleque V, Fraile LM, Bragado P, Gutierrez-Uzquiza A, Gordillo N, Garcia G, Castro Novais J, Perez Moreno JM, Mayorga Ortiz L, Ilundain Idoate A, Cremades Sendino M, Ares C, Miralbell R, Schreuder N. Biological and Mechanical Synergies to Deal With Proton Therapy Pitfalls: Minibeams, FLASH, Arcs, and Gantryless Rooms. Front Oncol 2021; 10:613669. [PMID: 33585238 PMCID: PMC7874206 DOI: 10.3389/fonc.2020.613669] [Citation(s) in RCA: 12] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/03/2020] [Accepted: 12/02/2020] [Indexed: 12/28/2022] Open
Abstract
Proton therapy has advantages and pitfalls comparing with photon therapy in radiation therapy. Among the limitations of protons in clinical practice we can selectively mention: uncertainties in range, lateral penumbra, deposition of higher LET outside the target, entrance dose, dose in the beam path, dose constraints in critical organs close to the target volume, organ movements and cost. In this review, we combine proposals under study to mitigate those pitfalls by using individually or in combination: (a) biological approaches of beam management in time (very high dose rate “FLASH” irradiations in the order of 100 Gy/s) and (b) modulation in space (a combination of mini-beams of millimetric extent), together with mechanical approaches such as (c) rotational techniques (optimized in partial arcs) and, in an effort to reduce cost, (d) gantry-less delivery systems. In some cases, these proposals are synergic (e.g., FLASH and minibeams), in others they are hardly compatible (mini-beam and rotation). Fixed lines have been used in pioneer centers, or for specific indications (ophthalmic, radiosurgery,…), they logically evolved to isocentric gantries. The present proposals to produce fixed lines are somewhat controversial. Rotational techniques, minibeams and FLASH in proton therapy are making their way, with an increasing degree of complexity in these three approaches, but with a high interest in the basic science and clinical communities. All of them must be proven in clinical applications.
Collapse
Affiliation(s)
| | | | - Daniel Sanchez-Parcerisa
- Grupo de Física Nuclear and IPARCOS, U. Complutense Madrid, CEI Moncloa, Madrid, Spain.,Instituto de Investigación Sanitaria del Hospital Clínico San Carlos, Madrid, Spain.,Sedecal Molecular Imaging, Madrid, Spain
| | - Jose Manuel Udias
- Grupo de Física Nuclear and IPARCOS, U. Complutense Madrid, CEI Moncloa, Madrid, Spain.,Instituto de Investigación Sanitaria del Hospital Clínico San Carlos, Madrid, Spain
| | - Samuel España
- Grupo de Física Nuclear and IPARCOS, U. Complutense Madrid, CEI Moncloa, Madrid, Spain.,Instituto de Investigación Sanitaria del Hospital Clínico San Carlos, Madrid, Spain
| | - Victor Sanchez-Tembleque
- Grupo de Física Nuclear and IPARCOS, U. Complutense Madrid, CEI Moncloa, Madrid, Spain.,Instituto de Investigación Sanitaria del Hospital Clínico San Carlos, Madrid, Spain
| | - Luis Mario Fraile
- Grupo de Física Nuclear and IPARCOS, U. Complutense Madrid, CEI Moncloa, Madrid, Spain.,Instituto de Investigación Sanitaria del Hospital Clínico San Carlos, Madrid, Spain
| | - Paloma Bragado
- Instituto de Investigación Sanitaria del Hospital Clínico San Carlos, Madrid, Spain.,Department of Biochemistry and Molecular Biology. U. Complutense, Madrid, Spain
| | - Alvaro Gutierrez-Uzquiza
- Instituto de Investigación Sanitaria del Hospital Clínico San Carlos, Madrid, Spain.,Department of Biochemistry and Molecular Biology. U. Complutense, Madrid, Spain
| | - Nuria Gordillo
- Department of Applied Physics, U. Autonoma de Madrid, Madrid, Spain.,Center for Materials Microanalysis, (CMAM), U. Autonoma de Madrid, Madrid, Spain
| | - Gaston Garcia
- Center for Materials Microanalysis, (CMAM), U. Autonoma de Madrid, Madrid, Spain
| | | | | | | | | | | | - Carme Ares
- Centro de Protonterapia Quironsalud, Madrid, Spain
| | | | | |
Collapse
|
6
|
Bertolet A, Carabe A. Proton monoenergetic arc therapy (PMAT) to enhance LETd within the target. Phys Med Biol 2020; 65:165006. [PMID: 32428896 DOI: 10.1088/1361-6560/ab9455] [Citation(s) in RCA: 12] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]
Abstract
We show the performance and feasibility of a proton arc technique so-called proton monoenergetic arc therapy (PMAT). Monoenergetic partial arcs are selected to place spots at the middle of a target and its potential to enhance the dose-averaged linear energy transfer (LETd) distribution within the target. Single-energy partial arcs in a single 360 degree gantry rotation are selected to deposit Bragg's peaks at the central part of the target to increase LETd values. An in-house inverse planning optimizer seeks for homogeneous doses at the target while keeping the dose to organs at risk (OARs) within constraints. The optimization consists of balancing the weights of spots coming out of selected partial arcs. A simple case of a cylindrical target in a phantom is shown to illustrate the method. Three different brain cancer cases are then considered to produce actual clinical plans, compared to those clinically used with pencil beam scanning (PBS). The relative biological effectiveness (RBE) is calculated according to the microdosimetric kinetic model (MKM). For the ideal case of a cylindrical target placed in a cylindrical phantom, the mean LETd in the target increases from 2.8 keV μm-1 to 4.0 keV μm-1 when comparing a three-field PBS plan with PMAT. This is replicated for clinical plans, increasing the mean RBE-weighted doses to the CTV by 3.1%, 1.7% and 2.5%, respectively, assuming an [Formula: see text] ratio equal to 10 Gy in the CTV. In parallel, LETd to OARs near the distal edge of the tumor decrease for all cases and metrics (mean LETd, LD,2% and LD,98%). The PMAT technique increases the LETd within the target, being feasible for the production of clinical plans meeting physical dosimetric requirements for both target and OARs. Thus, PMAT increases the RBE within the target, which may lead to a widening of the therapeutic index in proton radiotherapy that would be highlighted for low [Formula: see text] ratios and hyperfractionated schedules.
Collapse
Affiliation(s)
- A Bertolet
- Department of Radiation Oncology, Hospital of The University of Pennsylvania, Philadelphia 19104, PA, United States of America
| | | |
Collapse
|
7
|
Gu W, Ruan D, Lyu Q, Zou W, Dong L, Sheng K. A novel energy layer optimization framework for spot-scanning proton arc therapy. Med Phys 2020; 47:2072-2084. [PMID: 32040214 DOI: 10.1002/mp.14083] [Citation(s) in RCA: 29] [Impact Index Per Article: 7.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/06/2019] [Revised: 01/21/2020] [Accepted: 02/04/2020] [Indexed: 01/07/2023] Open
Abstract
PURPOSE Spot-scanning proton arc therapy (SPAT) is an emerging modality to improve plan conformality and delivery efficiency. A greedy and heuristic method is proposed in the existing SPAT algorithm to select energy layers and sequence energy switching with gantry rotation, which does not promise optimality in either dosimetry or efficiency. We aim to develop a method to solve the energy layer switching and dosimetry optimization problems in an integrated framework for SPAT. METHODS In an integrated approach, energy layer optimization for spot-scanning proton arc therapy (ELO-SPAT) is formulated with a dose fidelity term, a group sparsity regularization, a log barrier regularization, and an energy sequencing (ES) penalty. The combination of L2,1/2-norm group sparsity regularization and log barrier function allows one energy layer being selected per control point. The ES regularization term sorts the delivery sequence from high energy to low energy to reduce the total energy layer switching time (ELST) and subsequently the total delivery time. Within the ES penalty, the gradient of layer weights between adjacent beams is first calculated along beam direction and then along energy direction. The gradients indicate energy switch patterns between two adjacent beams. The time-wise costly energy switch-up is more heavily penalized in the ES term. This ELO-SPAT method was tested on one frontal base-of-skull (BOS) patient, one chordoma (CHDM) patient with a simultaneous integrated boost, one bilateral head-and-neck (H&N) patient, and one lung (LNG) patient. We compared ELO-SPAT with intensity-modulated proton therapy (IMPT) using discrete beams and SPArc by Ding et al. For the two arc algorithms, both the plans with and without energy sequencing were created and compared. RESULTS Energy layer optimization for spot-scanning proton arc therapy reduced the runtime of optimization by 84% on average compared with the greedy SPArc method. In both the ELO-SPAT plans with and without ES, one energy layer per control point was selected. Without ES regularization, the energy sequence was arbitrary, with around 40-60 switch-up for the tested cases. After adding ES regularization, the number of energy switch-up was reduced to less than 20. Compared with the energy sequenced SPArc plans, the ELO-SPAT plans with ES led to 24% less total ELST for synchrotron plans and 14% less for cyclotron plans. Both the ELO-SPAT and SPArc plans achieved better sparing compared with the IMPT plans for most Organs-at-risks (OARs), with or without ES. Without ES, the ELO-SPAT plans achieved further improvement of the OARs compared with the SPArc plans, with an averaged reduction of OAR [Dmean, Dmax] by [1.57, 3.34] GyRBE. Adding the ES regularization degraded the plan quality, but the ELO-SPAT plans still had comparable or slightly better sparing than the SPArc plans with ES, with an averaged reduction of OAR [Dmean, Dmax] by [1.42, 2.34] GyRBE. CONCLUSION We developed a computationally efficient spot-scanning proton arc optimization method, which solved energy layer selection and sequencing in an integrated framework, generating plans with good dosimetry and high delivery efficiency.
Collapse
Affiliation(s)
- Wenbo Gu
- Department of Radiation Oncology, University of California-Los Angeles, Los Angeles, CA, 90095, USA
| | - Dan Ruan
- Department of Radiation Oncology, University of California-Los Angeles, Los Angeles, CA, 90095, USA
| | - Qihui Lyu
- Department of Radiation Oncology, University of California-Los Angeles, Los Angeles, CA, 90095, USA
| | - Wei Zou
- Department of Radiation Oncology, University of Pennsylvania, Philadelphia, PA, 19104, USA
| | - Lei Dong
- Department of Radiation Oncology, University of Pennsylvania, Philadelphia, PA, 19104, USA
| | - Ke Sheng
- Department of Radiation Oncology, University of California-Los Angeles, Los Angeles, CA, 90095, USA
| |
Collapse
|
8
|
Carabe-Fernandez A, Bertolet-Reina A, Karagounis I, Huynh K, Dale RG. Is there a role for arcing techniques in proton therapy? Br J Radiol 2020; 93:20190469. [PMID: 31860338 PMCID: PMC7066964 DOI: 10.1259/bjr.20190469] [Citation(s) in RCA: 16] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/23/2019] [Revised: 11/26/2019] [Accepted: 12/18/2019] [Indexed: 01/01/2023] Open
Abstract
Proton arc therapy (PAT) has been proposed as a possible evolution for proton therapy. This commentary uses dosimetric and cancer risk evaluations from earlier studies to compare PAT with intensity modulated proton therapy. It is concluded that, although PAT may not produce better physical dose distributions than intensity modulated proton therapy, the radiobiological considerations associated with particular PAT techniques could offer the possibility of an increased therapeutic index.
Collapse
Affiliation(s)
| | | | - Ilias Karagounis
- Department
of Radiation Oncology, University of Pennsylvania,
Philadelphia, USA
| | - Kiet Huynh
- Department
of Radiation Oncology, University of Pennsylvania,
Philadelphia, USA
| | - Roger G Dale
- Department
of Surgery and Cancer, Faculty of Medicine, Imperial College,
London, UK
| |
Collapse
|
9
|
Smith BR, Hyer DE, Flynn RT, Hill PM, Culberson WS. Trimmer sequencing time minimization during dynamically collimated proton therapy using a colony of cooperating agents. Phys Med Biol 2019; 64:205025. [PMID: 31484170 DOI: 10.1088/1361-6560/ab416d] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
The dynamic collimation system (DCS) can be combined with pencil beam scanning proton therapy to deliver highly conformal treatment plans with unique collimation at each energy layer. This energy layer-specific collimation is accomplished through the synchronized motion of four trimmer blades that intercept the proton beam near the target boundary in the beam's eye view. However, the corresponding treatment deliveries come at the cost of additional treatment time since the translational speed of the trimmer is slower than the scanning speed of the proton pencil beam. In an attempt to minimize the additional trimmer sequencing time of each field while still maintaining a high degree of conformity, a novel process utilizing ant colony optimization (ACO) methods was created to determine the most efficient route of trimmer sequencing and beamlet scanning patterns for a collective set of collimated proton beamlets. The ACO process was integrated within an in-house treatment planning system optimizer to determine the beam scanning and DCS trimmer sequencing patterns and compared against an analytical approximation of the trimmer sequencing time should a contour-like scanning approach be assumed instead. Due to the stochastic nature of ACO, parameters where determined so that they could ensure good convergence and an efficient optimization of trimmer sequencing that was faster than an analytical contour-like trimmer sequencing. The optimization process was tested using a set of three intracranial treatment plans which were planned using a custom research treatment planning system and were successfully optimized to reduce the additional trimmer sequencing time to approximately 60 s per treatment field while maintaining a high degree of target conformity. Thus, the novel use of ACO techniques within a treatment planning algorithm has been demonstrated to effectively determine collimation sequencing patterns for a DCS in order to minimize the additional treatment time required for trimmer movement during treatment.
Collapse
Affiliation(s)
- Blake R Smith
- Department of Medical Physics, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, Wisconsin 53705. Author to whom correspondence should be addressed
| | | | | | | | | |
Collapse
|
10
|
Smith BR, Hyer DE, Flynn RT, Culberson WS. Technical Note: Optimization of spot and trimmer position during dynamically collimated proton therapy. Med Phys 2019; 46:1922-1930. [PMID: 30740709 DOI: 10.1002/mp.13441] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/28/2018] [Revised: 02/01/2019] [Accepted: 02/02/2019] [Indexed: 11/05/2022] Open
Abstract
PURPOSE To demonstrate a novel theoretical optimization design which considers beam spot and trimmer positioning in addition to beamlet weighting for dynamically collimated proton therapy (DCPT) treatments. Prior to this, the previous methods of plan optimization used to study this emerging technology relied upon an intuitive selection criterion to fix the trimmers blades for a uniform grid of beam spots before determining the individual beamlet weights. To evaluate the potential benefit from this new optimization design, a treatment planning optimization study was performed in order to compare the algorithm's functionality against the existing methods of plan optimization. MATERIALS AND METHODS A direct parameter optimization (DPO) method was developed to determine beam spot and trimmer positions cohesively with beamlet weighting for DCPT treatment plans. Gradients were numerically determined from applying small adjustments to the aforementioned parameters and quantifying the resulting impact on an objective function. This technique was compared to the conventional trimmer selection algorithm (TSA) which does not optimize spot position concurrently with trimmer position. Both planning methods were used to optimize a set of brain treatment plans, and the resulting dose distributions were compared with dose-volume histogram quantities in addition to target coverage, homogeneity, and conformity metrics. RESULTS An overall improvement to the target conformity and healthy tissue sparing was achieved with DPO over TSA while maintaining an equivalent planning target volume (PTV) coverage index for the three brain patients evaluated in this study. On average, the conformity index improved by 5.5% when utilizing DPO. A similar improvement in reducing the dose to several organs at risk was also noted. CONCLUSION Both the TSA and DPO planning methods can achieve highly conformal treatments with the dynamic collimation system (DCS) technology. However, an improvement in the target conformity and healthy tissue sparing was achieved by simultaneously optimizing beam spot position, trimmer location, and beamlet weights using DPO in comparison to the TSA technique.
Collapse
Affiliation(s)
- Blake R Smith
- Department of Medical Physics, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, WI, 53705, USA
| | - Daniel E Hyer
- Department of Radiation Oncology, University of Iowa, Iowa City, IA, 52242, USA
| | - Ryan T Flynn
- Department of Radiation Oncology, University of Iowa, Iowa City, IA, 52242, USA
| | - Wesley S Culberson
- Department of Medical Physics, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, WI, 53705, USA
| |
Collapse
|
11
|
Smith BR, Hyer DE, Hill PM, Culberson WS. Secondary Neutron Dose From a Dynamic Collimation System During Intracranial Pencil Beam Scanning Proton Therapy: A Monte Carlo Investigation. Int J Radiat Oncol Biol Phys 2018; 103:241-250. [PMID: 30114462 DOI: 10.1016/j.ijrobp.2018.08.012] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/12/2018] [Revised: 07/25/2018] [Accepted: 08/04/2018] [Indexed: 01/01/2023]
Abstract
PURPOSE Patients receiving pencil beam scanning (PBS) proton therapy with the addition of a dynamic collimation system (DCS) are potentially subject to an additional neutron dose from interactions between the incident proton beam and the trimmer blades. This study investigates the secondary neutron dose rates for both single-field uniform dose (SFUD) and intensity modulated proton therapy treatments. METHODS AND MATERIALS Secondary neutron dose distributions were calculated for both a dynamically collimated and an uncollimated, dual-field chordoma treatment plan and compared with previously published neutron dose rates from other contemporary scanning treatment modalities. Monte Carlo N-Particle transport code was used to track all primary and secondary particles generated from nuclear reactions within the DCS during treatment through a model of the patient geometry acquired from the computed tomography planning data set. Secondary neutron ambient dose equivalent distributions were calculated throughout the patient using a meshgrid with a tally resolution equivalent to that of the treatment planning computed tomography. RESULTS The median healthy-brain neutron ambient dose equivalent for a dynamically collimated intracranial chordoma treatment plan using a DCS was found to be 0.97 mSv/Gy for the right lateral SFUD field, 1.37 mSv/Gy for the apex SFUD field, and 1.24 mSv/Gy for the composite intensity modulated proton therapy distribution from 2 fields. CONCLUSIONS These results were at least 55% lower than what has been reported for uniform scanning modalities with brass apertures. However, they still reflect an increase in the excess relative risk of secondary cancer incidence compared with an uncollimated PBS treatment using only a graphite range shifter. Regardless, the secondary neutron dose expected from the DCS for these PBS proton therapy treatments appears to be on the order of, or below, what is expected for alternative collimated proton therapy techniques.
Collapse
Affiliation(s)
- Blake R Smith
- Department of Medical Physics, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, Wisconsin.
| | - Daniel E Hyer
- Department of Radiation Oncology, University of Iowa, Iowa City, Iowa
| | - Patrick M Hill
- Department of Human Oncology, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, Wisconsin
| | - Wesley S Culberson
- Department of Medical Physics, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, Wisconsin
| |
Collapse
|
12
|
Analysis of therapeutic effectiveness attained through generation of three alpha particles in proton-boron fusion reaction based on Monte Carlo simulation code. J Radioanal Nucl Chem 2018. [DOI: 10.1007/s10967-018-5813-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
|
13
|
Sanchez-Parcerisa D, Kirk M, Fager M, Burgdorf B, Stowe M, Solberg T, Carabe A. Range optimization for mono- and bi-energetic proton modulated arc therapy with pencil beam scanning. Phys Med Biol 2016; 61:N565-N574. [PMID: 27740944 DOI: 10.1088/0031-9155/61/21/n565] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Abstract
The development of rotational proton therapy plans based on a pencil-beam-scanning (PBS) system has been limited, among several other factors, by the energy-switching time between layers, a system-dependent parameter that ranges between a fraction of a second and several seconds. We are investigating mono- and bi-energetic rotational proton modulated arc therapy (PMAT) solutions that would not be affected by long energy switching times. In this context, a systematic selection of the optimal proton energy for each arc is vital. We present a treatment planning comparison of four different range selection methods, analyzing the dosimetric outcomes of the resulting treatment plans created with the ranges obtained. Given the patient geometry and arc definition (gantry and couch trajectories, snout elevation) our in-house treatment planning system (TPS) FoCa was used to find the maximum, medial and minimum water-equivalent thicknesses (WETs) of the target viewed from all possible field orientations. Optimal ranges were subsequently determined using four methods: (1) by dividing the max/min WET interval into equal steps, (2) by taking the average target midpoints from each field, (3) by taking the average WET of all voxels from all field orientations, and (4) by minimizing the fraction of the target which cannot be reached from any of the available angles. After the range (for mono-energetic plans) or ranges (for bi-energetic plans) were selected, the commercial clinical TPS in use in our institution (Varian Eclipse™) was used to produce the PMAT plans using multifield optimization. Linear energy transfer (LET) distributions of all plans were also calculated using FoCa and compared among the different methods. Mono- and bi-energetic PMAT plans, composed of a single 180° arc, were created for two patient geometries: a C-shaped target located in the mediastinal area of a thoracic tissue-equivalent phantom and a small brain tumor located directly above the brainstem. All plans were optimized using the same procedure to (1) achieve target coverage, (2) reduce dose to OAR and (3) limit dose hot spots in the target. Final outcomes were compared in terms of the resulting dose and LET distributions. Data shows little significant differences among the four studied methods, with superior results obtained with mono-energetic plans. A streamlined systematic method has been implemented in an in-house TPS to find the optimal range to maximize target coverage with rotational mono- or bi-energetic PBS rotational plans by minimizing the fraction of the target that cannot be reached by any direction.
Collapse
Affiliation(s)
- Daniel Sanchez-Parcerisa
- Department of Radiation Oncology, Hospital of the University of Pennsylvania, 3400 Civic Center Bvd, PA, USA. Departamento de Física Atómica, Molecular y Nuclear, Facultad de Ciencias Físicas, Universidad Complutense de Madrid, Av. Complutense s/n, 28040 Madrid, Spain
| | | | | | | | | | | | | |
Collapse
|
14
|
Spot-Scanning Proton Arc (SPArc) Therapy: The First Robust and Delivery-Efficient Spot-Scanning Proton Arc Therapy. Int J Radiat Oncol Biol Phys 2016; 96:1107-1116. [PMID: 27869083 DOI: 10.1016/j.ijrobp.2016.08.049] [Citation(s) in RCA: 84] [Impact Index Per Article: 10.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/12/2016] [Revised: 08/25/2016] [Accepted: 08/30/2016] [Indexed: 12/25/2022]
Abstract
PURPOSE To present a novel robust and delivery-efficient spot-scanning proton arc (SPArc) therapy technique. METHODS AND MATERIALS A SPArc optimization algorithm was developed that integrates control point resampling, energy layer redistribution, energy layer filtration, and energy layer resampling. The feasibility of such a technique was evaluated using sample patients: 1 patient with locally advanced head and neck oropharyngeal cancer with bilateral lymph node coverage, and 1 with a nonmobile lung cancer. Plan quality, robustness, and total estimated delivery time were compared with the robust optimized multifield step-and-shoot arc plan without SPArc optimization (Arcmulti-field) and the standard robust optimized intensity modulated proton therapy (IMPT) plan. Dose-volume histograms of target and organs at risk were analyzed, taking into account the setup and range uncertainties. Total delivery time was calculated on the basis of a 360° gantry room with 1 revolutions per minute gantry rotation speed, 2-millisecond spot switching time, 1-nA beam current, 0.01 minimum spot monitor unit, and energy layer switching time of 0.5 to 4 seconds. RESULTS The SPArc plan showed potential dosimetric advantages for both clinical sample cases. Compared with IMPT, SPArc delivered 8% and 14% less integral dose for oropharyngeal and lung cancer cases, respectively. Furthermore, evaluating the lung cancer plan compared with IMPT, it was evident that the maximum skin dose, the mean lung dose, and the maximum dose to ribs were reduced by 60%, 15%, and 35%, respectively, whereas the conformity index was improved from 7.6 (IMPT) to 4.0 (SPArc). The total treatment delivery time for lung and oropharyngeal cancer patients was reduced by 55% to 60% and 56% to 67%, respectively, when compared with Arcmulti-field plans. CONCLUSION The SPArc plan is the first robust and delivery-efficient proton spot-scanning arc therapy technique, which could potentially be implemented into routine clinical practice.
Collapse
|
15
|
Gelover E, Wang D, Hill PM, Flynn RT, Gao M, Laub S, Pankuch M, Hyer DE. A method for modeling laterally asymmetric proton beamlets resulting from collimation. Med Phys 2016; 42:1321-34. [PMID: 25735287 DOI: 10.1118/1.4907965] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
Abstract
PURPOSE To introduce a method to model the 3D dose distribution of laterally asymmetric proton beamlets resulting from collimation. The model enables rapid beamlet calculation for spot scanning (SS) delivery using a novel penumbra-reducing dynamic collimation system (DCS) with two pairs of trimmers oriented perpendicular to each other. METHODS Trimmed beamlet dose distributions in water were simulated with MCNPX and the collimating effects noted in the simulations were validated by experimental measurement. The simulated beamlets were modeled analytically using integral depth dose curves along with an asymmetric Gaussian function to represent fluence in the beam's eye view (BEV). The BEV parameters consisted of Gaussian standard deviations (sigmas) along each primary axis (σ(x1),σ(x2),σ(y1),σ(y2)) together with the spatial location of the maximum dose (μ(x),μ(y)). Percent depth dose variation with trimmer position was accounted for with a depth-dependent correction function. Beamlet growth with depth was accounted for by combining the in-air divergence with Hong's fit of the Highland approximation along each axis in the BEV. RESULTS The beamlet model showed excellent agreement with the Monte Carlo simulation data used as a benchmark. The overall passing rate for a 3D gamma test with 3%/3 mm passing criteria was 96.1% between the analytical model and Monte Carlo data in an example treatment plan. CONCLUSIONS The analytical model is capable of accurately representing individual asymmetric beamlets resulting from use of the DCS. This method enables integration of the DCS into a treatment planning system to perform dose computation in patient datasets. The method could be generalized for use with any SS collimation system in which blades, leaves, or trimmers are used to laterally sharpen beamlets.
Collapse
Affiliation(s)
- Edgar Gelover
- Department of Radiation Oncology, University of Iowa, 200 Hawkins Drive, Iowa City, Iowa 52242
| | - Dongxu Wang
- Department of Radiation Oncology, University of Iowa, 200 Hawkins Drive, Iowa City, Iowa 52242
| | - Patrick M Hill
- Department of Human Oncology, University of Wisconsin, 600 Highland Avenue, Madison, Wisconsin 53792
| | - Ryan T Flynn
- Department of Radiation Oncology, University of Iowa, 200 Hawkins Drive, Iowa City, Iowa 52242
| | - Mingcheng Gao
- Division of Medical Physics, CDH Proton Center, 4455 Weaver Parkway, Warrenville, Illinois 60555
| | - Steve Laub
- Division of Medical Physics, CDH Proton Center, 4455 Weaver Parkway, Warrenville, Illinois 60555
| | - Mark Pankuch
- Division of Medical Physics, CDH Proton Center, 4455 Weaver Parkway, Warrenville, Illinois 60555
| | - Daniel E Hyer
- Department of Radiation Oncology, University of Iowa, 200 Hawkins Drive, Iowa City, Iowa 52242
| |
Collapse
|
16
|
Moignier A, Gelover E, Wang D, Smith B, Flynn R, Kirk M, Lin L, Solberg T, Lin A, Hyer D. Improving Head and Neck Cancer Treatments Using Dynamic Collimation in Spot Scanning Proton Therapy. Int J Part Ther 2016; 2:544-554. [PMID: 31772966 DOI: 10.14338/ijpt-15-00026.1] [Citation(s) in RCA: 21] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/05/2015] [Accepted: 01/11/2016] [Indexed: 12/12/2022] Open
Abstract
Purpose Interest in using collimation for spot scanning proton therapy has recently increased in an attempt to improve the lateral penumbra. To investigate the advantages of such an approach for complex targets, a plan comparison between uncollimated and collimated beam spots was performed for patients with head and neck cancer. Patients and Methods For 10 patients with head and neck cancer, previously treated with spot scanning proton therapy, uncollimated and collimated treatment plans were created using an in-house treatment-planning system capable of modeling asymmetric-beamlet dose distributions resulting from the use of a dynamic collimation system. Both uncollimated and collimated plans reproduced clinically delivered plans in terms of target coverage. A relative plan comparison was performed using both physical and radiobiological metrics on the organs at risk. Results The dynamic collimation system improved dose-distribution conformity while preserving target coverage. The median reduction of the mean dose to the esophagus, uninvolved larynx, and uninvolved parotids were -11.9% (minimum to maximum, -6.4% to -24.1%), -7.2% (-0.8% to -60.1%), and -5.2% (-0.2% to -21.5%), respectively, and depended on the organ location relative to the target and radiation beam angle. The collimation did not improve dose to some organs at risk surrounded by the target or located upstream of Bragg peaks because of the priority on the target coverage. Conclusion In spot scanning proton therapy, the dynamic collimation system generally affords better target conformity, which results in improvement in organ-at-risk sparing in the head and neck region while preserving target coverage. However, the benefits of collimation and the increased complexity should be considered for each patient. Patients with large bilateral targets or organs at risk surrounded by the target showed the least benefit.
Collapse
Affiliation(s)
- Alexandra Moignier
- Department of Radiation Oncology, University of Iowa Hospitals and Clinics, Iowa City, IA, USA
| | - Edgar Gelover
- Department of Radiation Oncology, University of Iowa Hospitals and Clinics, Iowa City, IA, USA
| | - Dongxu Wang
- Department of Radiation Oncology, University of Iowa Hospitals and Clinics, Iowa City, IA, USA
| | - Blake Smith
- Department of Radiation Oncology, University of Iowa Hospitals and Clinics, Iowa City, IA, USA
| | - Ryan Flynn
- Department of Radiation Oncology, University of Iowa Hospitals and Clinics, Iowa City, IA, USA
| | - Maura Kirk
- Department of Radiation Oncology, University of Pennsylvania, Philadelphia, PA, USA
| | - Liyong Lin
- Department of Radiation Oncology, University of Pennsylvania, Philadelphia, PA, USA
| | - Timothy Solberg
- Department of Radiation Oncology, University of Pennsylvania, Philadelphia, PA, USA
| | - Alexander Lin
- Department of Radiation Oncology, University of Pennsylvania, Philadelphia, PA, USA
| | - Daniel Hyer
- Department of Radiation Oncology, University of Iowa Hospitals and Clinics, Iowa City, IA, USA
| |
Collapse
|
17
|
Barragán AM, Differding S, Janssens G, Lee JA, Sterpin E. Feasibility and robustness of dose painting by numbers in proton therapy with contour-driven plan optimization. Med Phys 2015; 42:2006-17. [PMID: 25832091 DOI: 10.1118/1.4915082] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
Abstract
PURPOSE To prove the ability of protons to reproduce a dose gradient that matches a dose painting by numbers (DPBN) prescription in the presence of setup and range errors, by using contours and structure-based optimization in a commercial treatment planning system. METHODS For two patients with head and neck cancer, voxel-by-voxel prescription to the target volume (GTVPET) was calculated from (18)FDG-PET images and approximated with several discrete prescription subcontours. Treatments were planned with proton pencil beam scanning. In order to determine the optimal plan parameters to approach the DPBN prescription, the effects of the scanning pattern, number of fields, number of subcontours, and use of range shifter were separately tested on each patient. Different constant scanning grids (i.e., spot spacing = Δx = Δy = 3.5, 4, and 5 mm) and uniform energy layer separation [4 and 5 mm WED (water equivalent distance)] were analyzed versus a dynamic and automatic selection of the spots grid. The number of subcontours was increased from 3 to 11 while the number of beams was set to 3, 5, or 7. Conventional PTV-based and robust clinical target volumes (CTV)-based optimization strategies were considered and their robustness against range and setup errors assessed. Because of the nonuniform prescription, ensuring robustness for coverage of GTVPET inevitably leads to overdosing, which was compared for both optimization schemes. RESULTS The optimal number of subcontours ranged from 5 to 7 for both patients. All considered scanning grids achieved accurate dose painting (1% average difference between the prescribed and planned doses). PTV-based plans led to nonrobust target coverage while robust-optimized plans improved it considerably (differences between worst-case CTV dose and the clinical constraint was up to 3 Gy for PTV-based plans and did not exceed 1 Gy for robust CTV-based plans). Also, only 15% of the points in the GTVPET (worst case) were above 5% of DPBN prescription for robust-optimized plans, while they were more than 50% for PTV plans. Low dose to organs at risk (OARs) could be achieved for both PTV and robust-optimized plans. CONCLUSIONS DPBN in proton therapy is feasible with the use of a sufficient number subcontours, automatically generated scanning patterns, and no more than three beams are needed. Robust optimization ensured the required target coverage and minimal overdosing, while PTV-approach led to nonrobust plans with excessive overdose. Low dose to OARs can be achieved even in the presence of a high-dose escalation as in DPBN.
Collapse
Affiliation(s)
- A M Barragán
- Center of Molecular Imaging, Radiotherapy and Oncology, Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain, Brussels B-1200, Belgium
| | - S Differding
- Center of Molecular Imaging, Radiotherapy and Oncology, Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain, Brussels B-1200, Belgium
| | - G Janssens
- Ion Beam Applications S.A., Louvain-la-Neuve 1348, Belgium
| | - J A Lee
- Center of Molecular Imaging, Radiotherapy and Oncology, Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain, Brussels B-1200, Belgium
| | - E Sterpin
- Center of Molecular Imaging, Radiotherapy and Oncology, Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain, Brussels B-1200, Belgium
| |
Collapse
|
18
|
Reducing the cost of proton radiation therapy: the feasibility of a streamlined treatment technique for prostate cancer. Cancers (Basel) 2015; 7:688-705. [PMID: 25920039 PMCID: PMC4491679 DOI: 10.3390/cancers7020688] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/16/2015] [Revised: 04/03/2015] [Accepted: 04/15/2015] [Indexed: 01/05/2023] Open
Abstract
Proton radiation therapy is an effective modality for cancer treatments, but the cost of proton therapy is much higher compared to conventional radiotherapy and this presents a formidable barrier to most clinical practices that wish to offer proton therapy. Little attention in literature has been paid to the costs associated with collimators, range compensators and hypofractionation. The objective of this study was to evaluate the feasibility of cost-saving modifications to the present standard of care for proton treatments for prostate cancer. In particular, we quantified the dosimetric impact of a treatment technique in which custom fabricated collimators were replaced with a multileaf collimator (MLC) and the custom range compensators (RC) were eliminated. The dosimetric impacts of these modifications were assessed for 10 patients with a commercial treatment planning system (TPS) and confirmed with corresponding Monte Carlo simulations. We assessed the impact on lifetime risks of radiogenic second cancers using detailed dose reconstructions and predictive dose-risk models based on epidemiologic data. We also performed illustrative calculations, using an isoeffect model, to examine the potential for hypofractionation. Specifically, we bracketed plausible intervals of proton fraction size and total treatment dose that were equivalent to a conventional photon treatment of 79.2 Gy in 44 fractions. Our results revealed that eliminating the RC and using an MLC had negligible effect on predicted dose distributions and second cancer risks. Even modest hypofractionation strategies can yield substantial cost savings. Together, our results suggest that it is feasible to modify the standard of care to increase treatment efficiency, reduce treatment costs to patients and insurers, while preserving high treatment quality.
Collapse
|
19
|
Wang D, Smith BR, Gelover E, Flynn RT, Hyer DE. A method to select aperture margin in collimated spot scanning proton therapy. Phys Med Biol 2015; 60:N109-19. [PMID: 25776926 DOI: 10.1088/0031-9155/60/7/n109] [Citation(s) in RCA: 21] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Abstract
The use of collimator or aperture may sharpen the lateral dose gradient for spot scanning proton therapy. However, to date, there has not been a standard method to determine the aperture margin for a single field in collimated spot scanning proton therapy. This study describes a theoretical framework to select the optimal aperture margin for a single field, and also presents the spot spacing limit required such that the optimal aperture margin exists. Since, for a proton pencil beam partially intercepted by collimator, the maximum point dose (spot center) shifts away from the original pencil beam central axis, we propose that the optimal margin should be equal to the maximum pencil beam center shift under the condition that spot spacing is small with respect to the maximum pencil beam center shift, which can be numerically determined based on beam modeling data. A test case is presented which demonstrates agreement with the prediction made based on the proposed methods. When apertures are applied in a commercial treatment planning system this method may be implemented.
Collapse
Affiliation(s)
- Dongxu Wang
- Department of Radiation Oncology, University of Iowa, 200 Hawkins Drive, Iowa City, IA 52242, USA
| | | | | | | | | |
Collapse
|
20
|
Adams QE, Xu J, Breitbach EK, Li X, Enger SA, Rockey WR, Kim Y, Wu X, Flynn RT. Interstitial rotating shield brachytherapy for prostate cancer. Med Phys 2014; 41:051703. [PMID: 24784369 DOI: 10.1118/1.4870441] [Citation(s) in RCA: 28] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
Abstract
PURPOSE To present a novel needle, catheter, and radiation source system for interstitial rotating shield brachytherapy (I-RSBT) of the prostate. I-RSBT is a promising technique for reducing urethra, rectum, and bladder dose relative to conventional interstitial high-dose-rate brachytherapy (HDR-BT). METHODS A wire-mounted 62 GBq(153)Gd source is proposed with an encapsulated diameter of 0.59 mm, active diameter of 0.44 mm, and active length of 10 mm. A concept model I-RSBT needle/catheter pair was constructed using concentric 50 and 75 μm thick nickel-titanium alloy (nitinol) tubes. The needle is 16-gauge (1.651 mm) in outer diameter and the catheter contains a 535 μm thick platinum shield. I-RSBT and conventional HDR-BT treatment plans for a prostate cancer patient were generated based on Monte Carlo dose calculations. In order to minimize urethral dose, urethral dose gradient volumes within 0-5 mm of the urethra surface were allowed to receive doses less than the prescribed dose of 100%. RESULTS The platinum shield reduced the dose rate on the shielded side of the source at 1 cm off-axis to 6.4% of the dose rate on the unshielded side. For the case considered, for the same minimum dose to the hottest 98% of the clinical target volume (D(98%)), I-RSBT reduced urethral D(0.1cc) below that of conventional HDR-BT by 29%, 33%, 38%, and 44% for urethral dose gradient volumes within 0, 1, 3, and 5 mm of the urethra surface, respectively. Percentages are expressed relative to the prescription dose of 100%. For the case considered, for the same urethral dose gradient volumes, rectum D(1cc) was reduced by 7%, 6%, 6%, and 6%, respectively, and bladder D(1cc) was reduced by 4%, 5%, 5%, and 6%, respectively. Treatment time to deliver 20 Gy with I-RSBT was 154 min with ten 62 GBq (153)Gd sources. CONCLUSIONS For the case considered, the proposed(153)Gd-based I-RSBT system has the potential to lower the urethral dose relative to HDR-BT by 29%-44% if the clinician allows a urethral dose gradient volume of 0-5 mm around the urethra to receive a dose below the prescription. A multisource approach is necessary in order to deliver the proposed (153)Gd-based I-RSBT technique in reasonable treatment times.
Collapse
Affiliation(s)
- Quentin E Adams
- Department of Radiation Oncology, University of Iowa, 200 Hawkins Drive, Iowa City, Iowa 52242
| | - Jinghzu Xu
- Department of Radiation Oncology, University of Iowa, 200 Hawkins Drive, Iowa City, Iowa 52242
| | - Elizabeth K Breitbach
- Department of Radiation Oncology, University of Iowa, 200 Hawkins Drive, Iowa City, Iowa 52242
| | - Xing Li
- Department of Radiation Oncology, University of Iowa, 200 Hawkins Drive, Iowa City, Iowa 52242
| | - Shirin A Enger
- Medical Physics Unit, McGill University, 1650 Cedar Ave, Montreal, Quebec H3G 1A4, Canada
| | - William R Rockey
- Department of Radiation Oncology, University of Iowa, 200 Hawkins Drive, Iowa City, Iowa 52242
| | - Yusung Kim
- Department of Radiation Oncology, University of Iowa, 200 Hawkins Drive, Iowa City, Iowa 52242
| | - Xiaodong Wu
- Department of Radiation Oncology, University of Iowa, 200 Hawkins Drive, Iowa City, Iowa 52242
| | - Ryan T Flynn
- Department of Radiation Oncology, University of Iowa, 200 Hawkins Drive, Iowa City, Iowa 52242
| |
Collapse
|
21
|
Abstract
PURPOSE To present dynamic rotating shield brachytherapy (D-RSBT), a novel form of high-dose-rate brachytherapy (HDR-BT) with electronic brachytherapy source, where the radiation shield is capable of changing emission angles during the radiation delivery process. METHODS A D-RSBT system uses two layers of independently rotating tungsten alloy shields, each with a 180° azimuthal emission angle. The D-RSBT planning is separated into two stages: anchor plan optimization and optimal sequencing. In the anchor plan optimization, anchor plans are generated by maximizing the D90 for the high-risk clinical-tumor-volume (HR-CTV) assuming a fixed azimuthal emission angle of 11.25°. In the optimal sequencing, treatment plans that most closely approximate the anchor plans under the delivery-time constraint will be efficiently computed. Treatment plans for five cervical cancer patients were generated for D-RSBT, single-shield RSBT (S-RSBT), and (192)Ir-based intracavitary brachytherapy with supplementary interstitial brachytherapy (IS + ICBT) assuming five treatment fractions. External beam radiotherapy doses of 45 Gy in 25 fractions of 1.8 Gy each were accounted for. The high-risk clinical target volume (HR-CTV) doses were escalated such that the D2cc of the rectum, sigmoid colon, or bladder reached its tolerance equivalent dose in 2 Gy fractions (EQD2 with α∕β = 3 Gy) of 75 Gy, 75 Gy, or 90 Gy, respectively. RESULTS For the patients considered, IS + ICBT had an average total dwell time of 5.7 minutes∕fraction (min∕fx) assuming a 10 Ci(192)Ir source, and the average HR-CTV D90 was 78.9 Gy. In order to match the HR-CTV D90 of IS + ICBT, D-RSBT required an average of 10.1 min∕fx more delivery time, and S-RSBT required 6.7 min∕fx more. If an additional 20 min∕fx of delivery time is allowed beyond that of the IS + ICBT case, D-RSBT and S-RSBT increased the HR-CTV D90 above IS + ICBT by an average of 16.3 Gy and 9.1 Gy, respectively. CONCLUSIONS For cervical cancer patients, D-RSBT can boost HR-CTV D90 over IS + ICBT and S-RSBT without violating the tolerance doses to the bladder, rectum, or sigmoid. The D90 improvements from D-RSBT depend on the patient, the delivery time budget, and the applicator structure.
Collapse
Affiliation(s)
- Yunlong Liu
- Department of Electrical and Computer Engineering, University of Iowa, 4016 Seamans Center, Iowa City, Iowa 52242
| | | | | | | | | |
Collapse
|
22
|
Rusten E, Rødal J, Bruland ØS, Malinen E. Biologic targets identified from dynamic 18FDG-PET and implications for image-guided therapy. Acta Oncol 2013; 52:1378-83. [PMID: 23981046 DOI: 10.3109/0284186x.2013.813071] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
PURPOSE The outcome of biologic image-guided radiotherapy depends on the definition of the biologic target. The purpose of the current work was to extract hyperperfused and hypermetabolic regions from dynamic positron emission tomography (D-PET) images, to dose escalate either region and to discuss implications of such image guided strategies. METHODS Eleven patients with soft tissue sarcomas were investigated with D-PET. The images were analyzed using a two-compartment model producing parametric maps of perfusion and metabolic rate. The two image series were segmented and exported to a treatment planning system, and biological target volumes BTVper and BTVmet (perfusion and metabolism, respectively) were generated. Dice's similarity coefficient was used to compare the two biologic targets. Intensity-modulated radiation therapy (IMRT) plans were generated for a dose painting by contours regime, where planning target volume (PTV) was planned to 60 Gy and BTV to 70 Gy. Thus, two separate plans were created for each patient with dose escalation of either BTVper or BTVmet. RESULTS BTVper was somewhat smaller than BTVmet (209 ± 170 cm(3) against 243 ± 143 cm(3), respectively; population-based mean and s.d.). Dice's coefficient depended on the applied margin, and was 0.72 ± 0.10 for a margin of 10 mm. Boosting BTVper resulted in mean dose of 69 ± 1.0 Gy to this region, while BTVmet received 67 ± 3.2 Gy. Boosting BTVmet gave smaller dose differences between the respective non-boost DVHs (such as D98). CONCLUSIONS Dose escalation of one of the BTVs results in a partial dose escalation of the other BTV as well. If tumor aggressiveness is equally pronounced in hyperperfused and hypermetabolic regions, this should be taken into account in the treatment planning.
Collapse
Affiliation(s)
- Espen Rusten
- Department of Physics, University of Oslo , Oslo , Norway
| | | | | | | |
Collapse
|
23
|
Liu Y, Flynn RT, Yang W, Kim Y, Bhatia SK, Sun W, Wu X. Rapid emission angle selection for rotating-shield brachytherapy. Med Phys 2013; 40:051720. [PMID: 23635268 DOI: 10.1118/1.4802750] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
Abstract
PURPOSE The authors present a rapid emission angle selection (REAS) method that enables the efficient selection of the azimuthal shield angle for rotating shield brachytherapy (RSBT). The REAS method produces a Pareto curve from which a potential RSBT user can select a treatment plan that balances the tradeoff between delivery time and tumor dose conformity. METHODS Two cervical cancer patients were considered as test cases for the REAS method. The RSBT source considered was a Xoft Axxent(TM) electronic brachytherapy source, partially shielded with 0.5 mm of tungsten, which traveled inside a tandem intrauterine applicator. Three anchor RSBT plans were generated for each case using dose-volume optimization, with azimuthal shield emission angles of 90°, 180°, and 270°. The REAS method converts the anchor plans to treatment plans for all possible emission angles by combining neighboring beamlets to form beamlets for larger emission angles. Treatment plans based on exhaustive dose-volume optimization (ERVO) and exhaustive surface optimization (ERSO) were also generated for both cases. Uniform dwell-time scaling was applied to all plans such that that high-risk clinical target volume D90 was maximized without violating the D2cc tolerances of the rectum, bladder, and sigmoid colon. RESULTS By choosing three azimuthal emission angles out of 32 potential angles, the REAS method performs about 10 times faster than the ERVO method. By setting D90 to 85-100 Gy10, the delivery times used by REAS generated plans are 21.0% and 19.5% less than exhaustive surface optimized plans used by the two clinical cases. By setting the delivery time budget to 5-25 and 10-30 min∕fx, respectively, for two the cases, the D90 contributions for REAS are improved by 5.8% and 5.1% compared to the ERSO plans. The ranges used in this comparison were selected in order to keep both D90 and the delivery time within acceptable limits. CONCLUSIONS The REAS method enables efficient RSBT treatment planning and delivery and provides treatment plans with comparable quality to those generated by exhaustive replanning with dose-volume optimization.
Collapse
Affiliation(s)
- Yunlong Liu
- Department of Electrical and Computer Engineering, University of Iowa, 4016 Seamans Center, Iowa City, Iowa 52242, USA
| | | | | | | | | | | | | |
Collapse
|
24
|
Rechner LA, Howell RM, Zhang R, Newhauser WD. Impact of margin size on the predicted risk of radiogenic second cancers following proton arc therapy and volumetric modulated arc therapy for prostate cancer. Phys Med Biol 2012; 57:N469-79. [PMID: 23154795 DOI: 10.1088/0031-9155/57/23/n469] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Abstract
We previously determined that the predicted risk of radiogenic second cancer in the bladder and rectum after proton arc therapy (PAT) was less than or equal to that after volumetric modulated arc therapy (VMAT) with photons, but we did not consider the impact of margin size on that risk. The current study was thus conducted to evaluate margin size's effect on the predicted risks of second cancer for the two modalities and the relative risk between them. Seven treatment plans with margins ranging from 0 mm in all directions to 6 mm posteriorly and 8 mm in all other directions were considered for both modalities. We performed risk analyses using three risk models with varying amounts of cell sterilization and calculated ratios of risk for the corresponding PAT and VMAT plans. We found that the change in risk with margin size depended on the risk model but that the relative risk remained nearly constant with margin size, regardless of the amount of cell sterilization modeled. We conclude that while margin size influences the predicted risk of a second cancer for a given modality, it appears to affect both modalities in roughly equal proportions so that the relative risk between PAT and VMAT is approximately equivalent.
Collapse
Affiliation(s)
- Laura A Rechner
- Department of Radiation Physics, Graduate School of Biomedical Sciences, The University of Texas Health Science Center Houston, Houston, TX 77030, USA
| | | | | | | |
Collapse
|
25
|
Rechner LA, Howell RM, Zhang R, Etzel C, Lee AK, Newhauser WD. Risk of radiogenic second cancers following volumetric modulated arc therapy and proton arc therapy for prostate cancer. Phys Med Biol 2012; 57:7117-32. [PMID: 23051714 DOI: 10.1088/0031-9155/57/21/7117] [Citation(s) in RCA: 30] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Abstract
Prostate cancer patients who undergo radiotherapy are at an increased risk to develop a radiogenic second cancer. Proton therapy has been shown to reduce the predicted risk of second cancer when compared to intensity modulated radiotherapy. However, it is unknown if this is also true for the rotational therapies proton arc therapy and volumetric modulated arc therapy (VMAT). The objective of this study was to compare the predicted risk of cancer following proton arc therapy and VMAT for prostate cancer. Proton arc therapy and VMAT plans were created for three patients. Various risk models were combined with the dosimetric data (therapeutic and stray dose) to predict the excess relative risk (ERR) of cancer in the bladder and rectum. Ratios of ERR values (RRR) from proton arc therapy and VMAT were calculated. RRR values ranged from 0.74 to 0.99, and all RRR values were shown to be statistically less than 1, except for the value calculated with the linear-non-threshold risk model. We conclude that the predicted risk of cancer in the bladder or rectum following proton arc therapy for prostate cancer is either less than or approximately equal to the risk following VMAT, depending on which risk model is applied.
Collapse
Affiliation(s)
- Laura A Rechner
- Graduate School of Biomedical Sciences, The University of Texas Health Science Center at Houston, Houston, TX 77030, USA
| | | | | | | | | | | |
Collapse
|
26
|
Zhang M, Flynn RT, Mo X, Mackie TR. The energy margin strategy for reducing dose variation due to setup uncertainty in intensity modulated proton therapy (IMPT) delivered with distal edge tracking (DET). J Appl Clin Med Phys 2012; 13:3863. [PMID: 22955652 PMCID: PMC4439946 DOI: 10.1120/jacmp.v13i5.3863] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/23/2011] [Revised: 05/06/2012] [Accepted: 05/05/2012] [Indexed: 12/14/2022] Open
Abstract
Intensity-modulated proton therapy (IMPT) can produce plans with similar target dose conformity but lower normal tissue dose than intensity-modulated X-ray therapy (IMXT). However, due to the finite range of proton beams in tissue, proton therapy treatment plans are usually more sensitive to setup uncertainties than X-ray therapy plans. In this work, the energy margin (EM) concept, which was initially developed for passive scattering proton therapy, was generalized to apply to IMPT treatment planning. The effectiveness of the EM method was evaluated on five head-and-neck cancer patients with distal edge tracking (DET) treatment plans by comparing the original plans (ORG) without an EM to those with an EM. Three beam arrangements were considered: 24 beams delivered over a 360° arc, 12 beams delivered over a 180° arc, and 12 beams delivered over two 90° fan angles. Setup uncertainty was modeled by sampling rigid translational shifts from a Gaussian distribution with a mean of 0 mm and standard deviation of 2 mm in all directions. Delivered dose distributions for all 30 fractions were recalculated using the Geant4 Monte Carlo code. Normalized total dose (NTD) for both the CTV and a ring structure surrounding the PTV were recorded. The plan quality comparison revealed that EM plans had the same CTV coverage but higher dose to the normal tissue than ORG plans. After the simulated delivery, ORG plans resulted in more than 3% underdosage to 5% of the CTV volume in all three beam arrangements, whereas the EM plans did not. Both ORG and EM plans did not produce more than 5% overdose to D2% of the ring structure. The use of an EM for IMPT treatment planning can substantially reduce sensitivity of the resulting dose distributions to setup uncertainty.
Collapse
Affiliation(s)
- Miao Zhang
- Department of Radiation Oncology,1 The Cancer Institute of New Jersey, UMDNJ-Robert Wood Johnson Medical School, New Brunswick, NJ 08901,USA.
| | | | | | | |
Collapse
|
27
|
Zhang M, Westerly DC, Mackie TR. Introducing an on-line adaptive procedure for prostate image guided intensity modulate proton therapy. Phys Med Biol 2011; 56:4947-65. [PMID: 21772078 DOI: 10.1088/0031-9155/56/15/019] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Abstract
With on-line image guidance (IG), prostate shifts relative to the bony anatomy can be corrected by realigning the patient with respect to the treatment fields. In image guided intensity modulated proton therapy (IG-IMPT), because the proton range is more sensitive to the material it travels through, the realignment may introduce large dose variations. This effect is studied in this work and an on-line adaptive procedure is proposed to restore the planned dose to the target. A 2D anthropomorphic phantom was constructed from a real prostate patient's CT image. Two-field laterally opposing spot 3D-modulation and 24-field full arc distal edge tracking (DET) plans were generated with a prescription of 70 Gy to the planning target volume. For the simulated delivery, we considered two types of procedures: the non-adaptive procedure and the on-line adaptive procedure. In the non-adaptive procedure, only patient realignment to match the prostate location in the planning CT was performed. In the on-line adaptive procedure, on top of the patient realignment, the kinetic energy for each individual proton pencil beam was re-determined from the on-line CT image acquired after the realignment and subsequently used for delivery. Dose distributions were re-calculated for individual fractions for different plans and different delivery procedures. The results show, without adaptive, that both the 3D-modulation and the DET plans experienced delivered dose degradation by having large cold or hot spots in the prostate. The DET plan had worse dose degradation than the 3D-modulation plan. The adaptive procedure effectively restored the planned dose distribution in the DET plan, with delivered prostate D(98%), D(50%) and D(2%) values less than 1% from the prescription. In the 3D-modulation plan, in certain cases the adaptive procedure was not effective to reduce the delivered dose degradation and yield similar results as the non-adaptive procedure. In conclusion, based on this 2D phantom study, by updating the proton pencil beam energy from the on-line image after realignment, this on-line adaptive procedure is necessary and effective for the DET-based IG-IMPT. Without dose re-calculation and re-optimization, it could be easily incorporated into the clinical workflow.
Collapse
Affiliation(s)
- M Zhang
- Department of Medical Physics, University of Wisconsin, Madison, WI 53705, USA.
| | | | | |
Collapse
|
28
|
Sengbusch ER, Mackie TR. Maximum kinetic energy considerations in proton stereotactic radiosurgery. J Appl Clin Med Phys 2011. [PMID: 21844866 PMCID: PMC4878444 DOI: 10.1120/jacmp.v12i3.3533] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022] Open
Abstract
The purpose of this study was to determine the maximum proton kinetic energy required to treat a given percentage of patients eligible for stereotactic radiosurgery (SRS) with coplanar arc‐based proton therapy, contingent upon the number and location of gantry angles used. Treatment plans from 100 consecutive patients treated with SRS at the University of Wisconsin Carbone Cancer Center between June of 2007 and March of 2010 were analyzed. For each target volume within each patient, in‐house software was used to place proton pencil beam spots over the distal surface of the target volume from 51 equally‐spaced gantry angles of up to 360°. For each beam spot, the radiological path length from the surface of the patient to the distal boundary of the target was then calculated along a ray from the gantry location to the location of the beam spot. This data was used to generate a maximum proton energy requirement for each patient as a function of the arc length that would be spanned by the gantry angles used in a given treatment. If only a single treatment angle is required, 100% of the patients included in the study could be treated by a proton beam with a maximum kinetic energy of 118 MeV. As the length of the treatment arc is increased to 90°, 180°, 270°, and 360°, the maximum energy requirement increases to 127, 145, 156, and 179 MeV, respectively. A very high percentage of SRS patients could be treated at relatively low proton energies if the gantry angles used in the treatment plan do not span a large treatment arc. Maximum proton kinetic energy requirements increase linearly with size of the treatment arc. PACS numbers: 87.55.‐x, 87.53.Ly, 87.53.Bn
Collapse
Affiliation(s)
- Evan R. Sengbusch
- Department of Medical Physics; University of Wisconsin School of Medicine and Public Health; Madison WI 53705
| | - Thomas R. Mackie
- Departments of Medical Physics; Human Oncology, Biomedical Engineering, and Engineering Physics; University of Wisconsin School of Medicine and Public Health; Madison WI 53705 USA
| |
Collapse
|
29
|
Price PM, Green MM. Positron emission tomography imaging approaches for external beam radiation therapies: current status and future developments. Br J Radiol 2011; 84 Spec No 1:S19-34. [PMID: 21427180 DOI: 10.1259/bjr/21263014] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/28/2023] Open
Abstract
In an era in which it is possible to deliver radiation with high precision, there is a heightened need for enhanced imaging capabilities to improve tumour localisation for diagnostic, planning and delivery purposes. This is necessary to increase the accuracy and overall efficacy of all types of external beam radiotherapy (RT), including particle therapies. Positron emission tomography (PET) has the potential to fulfil this need by imaging fundamental aspects of tumour biology. The key areas in which PET may support the RT process include improving disease diagnosis and staging; assisting tumour volume delineation; defining tumour phenotype or biological tumour volume; assessment of treatment response; and in-beam monitoring of radiation dosimetry. The role of PET and its current developmental status in these key areas are overviewed in this review, highlighting the advantages and drawbacks.
Collapse
Affiliation(s)
- P M Price
- Department of Academic Radiation Oncology, The University of Manchester, The Christie Hospital NHS Foundation Trust, Manchester, UK.
| | | |
Collapse
|
30
|
Abstract
The rapid phosphorylation of histone H2AX at serine 139 (γH2AX) serves as a sensitive marker for DNA double-strand breaks induced by ionizing radiation or other genotoxic agents. The potential clinical applications of γH2AX detection in tissues from cancer patients during fractionated radiotherapy and the sensitivity for detection of in vivo drug effects on radiation-induced DNA damage responses (DDRs) are discussed. The quantification of γH2AX foci in the nuclei of peripheral blood lymphocytes allows estimation of the applied integral body dose by conformal radiotherapy to tumors in different sites of the body. The limits of precision of biodosimetry in peripheral blood lymphocytes with a γH2AX assay shortly after radiation exposure are shown. The high sensitivity of the in vitro radiation dose-γH2AX foci response allows monitoring of drug effects on DDR pathways after in vivo drug exposure and in vitro irradiation. Drugs are under clinical investigation that modify radiation-induced damage response. If interindividual or intertumoral differences in drug sensitivity exist, the measurement of radiation-induced foci formation and resolution after in vivo drug exposure and in vitro or in vivo irradiation of a cellular probe can serve as a functional assay that may predict the individual gain of a combination therapy. Validation by prospective studies is needed.
Collapse
|
31
|
Basics of particle therapy II biologic and dosimetric aspects of clinical hadron therapy. Am J Clin Oncol 2011; 33:646-9. [PMID: 20395789 DOI: 10.1097/coc.0b013e3181cdf0fe] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
Besides photons and electrons, high-energy particles like protons, neutrons, ⁴He ions or heavier ions (C, Ne, etc) have been finding increasing applications in the treatment of radioresistant tumors and tumors located near critical structures. The main difference between photons and hadrons is their different biologic effect and depth-dose distribution. Generally speaking, protons are superior in dosimetric aspects whereas neutrons have advantages in biologic effectiveness because of the high linear energy transfer. In 1946 Robert Wilson first published the physical advantages in dose distribution of ion particles for cancer therapy. Since that time hadronic radiotherapy has been intensively studied in physics laboratories worldwide and clinical application have gradually come to fruition. Hadron therapy was made possible by the advances in accelerator technology, which increases the particles' energy high enough to place them at any depth within the patient's body. As a follow-up to the previous article Introduction to Hadrons, this review discusses certain biologic and dosimetric aspects of using protons, neutrons, and heavy charged particles for radiation therapy.
Collapse
|
32
|
Schwarz M, Pierelli A, Fiorino C, Fellin F, Cattaneo GM, Cozzarini C, Muzio ND, Calandrino R, Widesott L. Helical tomotherapy and intensity modulated proton therapy in the treatment of early stage prostate cancer: A treatment planning comparison. Radiother Oncol 2011; 98:74-80. [DOI: 10.1016/j.radonc.2010.10.027] [Citation(s) in RCA: 30] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/16/2009] [Revised: 10/25/2010] [Accepted: 10/26/2010] [Indexed: 11/30/2022]
|
33
|
Yang W, Jones R, Read P, Benedict S, Sheng K. Standardized evaluation of simultaneous integrated boost plans on volumetric modulated arc therapy. Phys Med Biol 2010; 56:327-39. [DOI: 10.1088/0031-9155/56/2/003] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
|
34
|
Rickhey M, Morávek Z, Eilles C, Koelbl O, Bogner L. 18F-FET-PET-based dose painting by numbers with protons. Strahlenther Onkol 2010; 186:320-6. [PMID: 20559789 DOI: 10.1007/s00066-010-2014-8] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/05/2009] [Accepted: 03/12/2010] [Indexed: 11/25/2022]
Abstract
PURPOSE To investigate the potential of (18)F-fluoroethyltyrosine-positron emission tomography-((18)F-FET-PET-)based dose painting by numbers with protons. MATERIAL AND METHODS Due to its high specificity to brain tumor cells, FET has a high potential to serve as a target for dose painting by numbers. Biological image-based dose painting might lead to an inhomogeneous dose prescription. For precise treatment planning of such a prescribed dose, an intensity-modulated radiotherapy (IMRT) algorithm including a Monte Carlo dose-calculation algorithm for spot-scanning protons was used. A linear tracer uptake to dose model was used to derive a dose prescription from the (18)F-FET-PET. As a first investigation, a modified modulation transfer function (MTF) of protons was evaluated and compared to the MTF of photons. In a clinically adapted planning study, the feasibility of (18)F-FET-PET-based dose painting with protons was demonstrated using three patients with glioblastome multiforme. The resulting dose distributions were evaluated by means of dose-difference and dose-volume histograms and compared to IMRT data. RESULTS The MTF for protons was constantly above that for photons. The standard deviations of the dose differences between the prescribed and the optimized dose were smaller in case of protons compared to photons. Furthermore, the escalation study showed that the doses within the subvolumes identified by biological imaging techniques could be escalated remarkably while the dose within the organs at risk was kept at a constant level. CONCLUSION The presented investigation fortifies the feasibility of (18)F-FET-PET-based dose painting with protons.
Collapse
Affiliation(s)
- Mark Rickhey
- Department of Radiotherapy, University of Regensburg, Regensburg, Germany.
| | | | | | | | | |
Collapse
|
35
|
Sengbusch E, Pérez-Andújar A, DeLuca PM, Mackie TR. Maximum proton kinetic energy and patient-generated neutron fluence considerations in proton beam arc delivery radiation therapy. Med Phys 2009; 36:364-72. [PMID: 19291975 DOI: 10.1118/1.3049787] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
Abstract
Several compact proton accelerator systems for use in proton therapy have recently been proposed. Of paramount importance to the development of such an accelerator system is the maximum kinetic energy of protons, immediately prior to entry into the patient, that must be reached by the treatment system. The commonly used value for the maximum kinetic energy required for a medical proton accelerator is 250 MeV, but it has not been demonstrated that this energy is indeed necessary to treat all or most patients eligible for proton therapy. This article quantifies the maximum kinetic energy of protons, immediately prior to entry into the patient, necessary to treat a given percentage of patients with rotational proton therapy, and examines the impact of this energy threshold on the cost and feasibility of a compact, gantry-mounted proton accelerator treatment system. One hundred randomized treatment plans from patients treated with IMRT were analyzed. The maximum radiological pathlength from the surface of the patient to the distal edge of the treatment volume was obtained for 180 degrees continuous arc proton therapy and for 180 degrees split arc proton therapy (two 90 degrees arcs) using CT# profiles from the Pinnacle (Philips Medical Systems, Madison, WI) treatment planning system. In each case, the maximum kinetic energy of protons, immediately prior to entry into the patient, that would be necessary to treat the patient was calculated using proton range tables for various media. In addition, Monte Carlo simulations were performed to quantify neutron production in a water phantom representing a patient as a function of the maximum proton kinetic energy achievable by a proton treatment system. Protons with a kinetic energy of 240 MeV, immediately prior to entry into the patient, were needed to treat 100% of patients in this study. However, it was shown that 90% of patients could be treated at 198 MeV, and 95% of patients could be treated at 207 MeV. Decreasing the proton kinetic energy from 250 to 200 MeV decreases the total neutron energy fluence produced by stopping a monoenergetic pencil beam in a water phantom by a factor of 2.3. It is possible to significantly lower the requirements on the maximum kinetic energy of a compact proton accelerator if the ability to treat a small percentage of patients with rotational therapy is sacrificed. This decrease in maximum kinetic energy, along with the corresponding decrease in neutron production, could lower the cost and ease the engineering constraints on a compact proton accelerator treatment facility.
Collapse
Affiliation(s)
- E Sengbusch
- Department of Medical Physics, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin 53706-1532, USA.
| | | | | | | |
Collapse
|
36
|
Søvik Å, Malinen E, Olsen DR. Strategies for Biologic Image-Guided Dose Escalation: A Review. Int J Radiat Oncol Biol Phys 2009; 73:650-8. [DOI: 10.1016/j.ijrobp.2008.11.001] [Citation(s) in RCA: 75] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/12/2008] [Revised: 10/30/2008] [Accepted: 11/03/2008] [Indexed: 11/17/2022]
|
37
|
Bowen SR, Flynn RT, Bentzen SM, Jeraj R. On the sensitivity of IMRT dose optimization to the mathematical form of a biological imaging-based prescription function. Phys Med Biol 2009; 54:1483-501. [PMID: 19218733 DOI: 10.1088/0031-9155/54/6/007] [Citation(s) in RCA: 51] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Abstract
Voxel-based prescriptions of deliberately non-uniform dose distributions based on molecular imaging, so-called dose painting or theragnostic radiation therapy, require specification of a transformation that maps the image data intensities to prescribed doses. However, the functional form of this transformation is currently unknown. An investigation into the sensitivity of optimized dose distributions resulting from several possible prescription functions was conducted. Transformations between the radiotracer activity concentrations from Cu-ATSM PET images, as a surrogate of tumour hypoxia, and dose prescriptions were implemented to yield weighted distributions of prescribed dose boosts in high uptake regions. Dose escalation was constrained to reflect clinically realistic whole tumour doses and constant normal tissue doses. Optimized heterogeneous dose distributions were found by minimizing a voxel-by-voxel quadratic objective function in which all tumour voxels were given equal weight. Prescriptions based on a polynomial mapping function were found to be least constraining on their optimized plans, while prescriptions based on a sigmoid mapping function were the most demanding to deliver. A prescription formalism that fixed integral dose was less sensitive to errors in the choice of the mapping function than one that boosted integral dose. Integral doses to normal tissue and critical structures were insensitive to the shape of the prescription function. Planned target dose conformity improved with smaller beamlet dimensions until the inherent spatial resolution of the functional image was matched. Clinical implementation of dose painting depends on advances in absolute quantification of functional images and improvements in delivery techniques over smaller spatial scales.
Collapse
Affiliation(s)
- Stephen R Bowen
- Department of Medical Physics, University of Wisconsin School of Medicine and Public Health, 1530 MSC, 1300 University Ave, Madison, WI 53706, USA.
| | | | | | | |
Collapse
|
38
|
|
39
|
Farr JB, Mascia AE, Hsi WC, Allgower CE, Jesseph F, Schreuder AN, Wolanski M, Nichiporov DF, Anferov V. Clinical characterization of a proton beam continuous uniform scanning system with dose layer stacking. Med Phys 2009; 35:4945-54. [PMID: 19070228 DOI: 10.1118/1.2982248] [Citation(s) in RCA: 81] [Impact Index Per Article: 5.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
Abstract
A proton beam delivery system on a gantry with continuous uniform scanning and dose layer stacking at the Midwest Proton Radiotherapy Institute has been commissioned and accepted for clinical use. This paper was motivated by a lack of guidance on the testing and characterization for clinical uniform scanning systems. As such, it describes how these tasks were performed with a uniform scanning beam delivery system. This paper reports the methods used and important dosimetric characteristics of radiation fields produced by the system. The commissioning data include the transverse and longitudinal dose distributions, penumbra, and absolute dose values. Using a 208 MeV cyclotron's proton beam, the system provides field sizes up to 20 and 30 cm in diameter for proton ranges in water up to 27 and 20 cm, respectively. The dose layer stacking method allows for the flexible construction of spread-out Bragg peaks with uniform modulation of up to 15 cm in water, at typical dose rates of 1-3 Gy/min. For measuring relative dose distributions, multielement ion chamber arrays, small-volume ion chambers, and radiographic films were employed. Measurements during the clinical commissioning of the system have shown that the lateral and longitudinal dose uniformity of 2.5% or better can be achieved for all clinically important field sizes and ranges. The measured transverse penumbra widths offer a slight improvement in comparison to those achieved with a double scattering beam spreading technique at the facility. Absolute dose measurements were done using calibrated ion chambers, thermoluminescent and alanine detectors. Dose intercomparisons conducted using various types of detectors traceable to a national standards laboratory indicate that the measured dosimetry data agree with each other within 5%.
Collapse
Affiliation(s)
- J B Farr
- Indiana University, Department of Physics, Swain Hall West, Room 117, 727 E. Third St., Bloomington, Indiana 47405, USA.
| | | | | | | | | | | | | | | | | |
Collapse
|
40
|
Flynn RT, Bowen SR, Bentzen SM, Rockwell Mackie T, Jeraj R. Intensity-modulated x-ray (IMXT) versus proton (IMPT) therapy for theragnostic hypoxia-based dose painting. Phys Med Biol 2008; 53:4153-67. [PMID: 18635895 DOI: 10.1088/0031-9155/53/15/010] [Citation(s) in RCA: 58] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/26/2023]
Abstract
In this work the abilities of intensity-modulated x-ray therapy (IMXT) and intensity-modulated proton therapy (IMPT) to deliver boosts based on theragnostic imaging were assessed. Theragnostic imaging is the use of functional or molecular imaging data for prescribing radiation dose distributions. Distal gradient tracking, an IMPT method designed for the delivery of non-uniform dose distributions, was assessed. Dose prescriptions for a hypoxic region in a head and neck squamous cell carcinoma patient were designed to either uniformly boost the region or redistribute the dose based on positron emission tomography (PET) images of the (61)Cu(II)-diacetyl-bis(N(4)-methylthiosemicarbazone) ((61)Cu-ATSM) hypoxia surrogate. Treatment plans for the prescriptions were created for four different delivery methods: IMXT delivered with step-and-shoot and with helical tomotherapy, and IMPT delivered with spot scanning and distal gradient tracking. IMXT and IMPT delivered comparable dose distributions within the boost region for both uniform and redistributed theragnostic boosts. Normal tissue integral dose was lower by a factor of up to 3 for IMPT relative to the IMXT. For all delivery methods, the mean dose to the nearby organs at risk changed by less than 2 Gy for redistributed versus uniform boosts. The distal gradient tracking method resulted in comparable plans to the spot scanning method while reducing the number of proton beam spots by a factor of over 3.
Collapse
Affiliation(s)
- Ryan T Flynn
- Department of Medical Physics, University of Wisconsin School of Medicine and Public Health, Madison, WI 53703, USA.
| | | | | | | | | |
Collapse
|